Merck and Daiichi Sankyo acknowledged a "voluntary pause" in the phase III program for the investigational antibody-drug conjugate ifinatamab deruxtecan following a higher-than-expected number of ...
NASA opens the International Space Station for scientists and researchers, inviting them to use the benefits of microgravity for private industry research, technology demonstrations, and more. Today, ...
Laura Huppert, MD, highlights patient-reported outcomes from the phase 3 ASCENT-04 trial which compared first-line treatment ...
Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.
Astellas Pharma announces positive topline results from phase 3 EV-304 clinical trial of Padcev plus Keytruda: Tokyo Friday, December 19, 2025, 10:00 Hrs [IST] Astellas Pharma Inc ...
Clinical Trials Arena on MSN
Padcev-Keytruda notches another phase III win in bladder cancer
Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s ...
Pyxis Oncology (PYXS) announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin, a first-in-concept ...
(ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® ...
“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.
Cytoreductive nephrectomy merits further consideration in appropriately risk-stratified, surgically fit patients with mRCC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results